Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BCMA Targeted CAR T Cells with or without Lenalidomide in Multiple Myeloma
NCT03070327Phase 1Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Feb 2017
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Prophylactic Vaccines, Gene Silencing
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous EGFRt/BCMA-41BBz CAR T cells in multiple myeloma (MM), sponsored by Memorial Sloan Kettering Cancer Center. Primary endpoint: Maximum Tolerated Dose at 36 months. Started Feb 2017; status: completed.
02
Drugs
autologous EGFRt/BCMA-41BBz CAR T cells
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT03070327.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03070327.